[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-alcoholic-fatty-liver-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-alcoholic-fatty-liver-diseases":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100563718",false,"NCT06619808","Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases","Efficacy and Safety of Hyperbaric Oxygen Therapy in Adult Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) Patients : a Randomized Controlled Trial","MASLD","Inclusion Criteria:\n\n* Metabolic dysfunction-associated steatotic liver disease patients\n\nExclusion Criteria:\n\n* Participants are unfit for hyperbaric treatment.\n* Participants with prior oxygen therapy within the last 6 months.\n* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.\n* Participants with severe organ dysfunctions or malignant tumors.\n* Participants have weight loss plan or major operations within the last 6 months.\n* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.\n* Participants are pregnant or lactating.\n* Participants with claustrophobia or that cannot decompress properly.","ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:\n\nDoes HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?\n\nParticipants will:\n\nReceive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.",[27,28,29],"Metabolic Dysfunction-associated Steatotic Liver Disease","Hepatic Steatosis","Non-alcoholic Fatty Liver Diseases",[27,31,29,32],"Hyperbaric Oxygen Therapy","Oxygen Therapy","RECRUITING","2024-09-28",{"date":36,"type":37},"2024-10-01","ACTUAL",{"date":39,"type":37},"2024-07-29",{"date":41,"type":21},"2026-08-31",{"name":43,"class":44},"Jinling Hospital, China","OTHER",""]